Castle Biosciences Insider Sale: 1,339 Shares Sold Under 10b5-1 Plan
Rhea-AI Filing Summary
Castle Biosciences director and CEO Derek J. Maetzold reported a sale of 1,339 shares of Castle Biosciences common stock executed under a Rule 10b5-1 plan at a weighted-average price of $20.04 per share. The filing states the sale was executed in multiple trades with prices ranging from $20.00 to $20.10 and that the reporting person will provide trade-level details upon request.
Following the reported transaction, the form discloses the reporting persons remaining direct and indirect beneficial ownership across trusts and vehicles, including 68,344 shares held directly and multiple indirect holdings (for example, 52,923, 44,986, 85,959, and others) held through family and grantor retained annuity trusts. The sale was made pursuant to a pre-established written plan adopted in May 2025.
Positive
- Transaction executed under a Rule 10b5-1 plan, providing an affirmative defense framework
- Transparent disclosure of weighted-average sale price and willingness to provide trade-level details on request
- Substantial retained holdings disclosed across direct and multiple indirect trusts, indicating continued ownership
Negative
- Insider sale of 1,339 shares reduced direct holdings (reported price $20.04 weighted-average)
- Limited signal value for interpreting insider intent because the sale was made pursuant to a pre-set plan
Insights
TL;DR: Insider sale of 1,339 shares under a 10b5-1 plan is a routine liquidity event and leaves the CEO with substantial direct and indirect holdings.
The transaction is small relative to the aggregate beneficial ownership disclosed and was executed under a pre-established trading plan, which limits informational value about future company prospects. The availability of trade-level price and quantity details upon request preserves transparency. Investors should view this as a compliance-driven sale rather than clear directional insider signal based solely on this filing.
TL;DR: Use of a Rule 10b5-1 plan indicates adherence to an accepted governance practice for scheduled insider transactions.
The filing explicitly cites a 10b5-1 plan adopted by the reporting person, which helps establish an affirmative defense against insider trading claims for transactions made under the plan. The detailed breakdown of direct and indirect holdings across multiple trusts demonstrates disclosure completeness. The signature via attorney-in-fact is noted, consistent with standard practice for Form 4 submissions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,339 | $20.04 | $27K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. This transaction was executed in multiple trades at prices ranging from $20.00 to 20.10, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by DJM Grantor Retained Annuity Trust No. 5 of which the Reporting Person is the trustee and beneficiary. Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
